Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADaPPt Trial: ADT De-escalation in High-Risk Prostate Cancer
NCT07777263Phase 3Not yet recruiting
- Sponsor
- Dr. Tamim Niazi
- Start
- Oct 2026
- Primary completion
- Oct 2035
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in prostate cancer (PCa) comparing Arm 1 (experimental): 12 months of ADT + Radiotherapy with Arm 2 (standard of care): 24 months of ADT + Radiotherapy (2 arms). Primary endpoint: Biochemical Failure-Free Survival at 5 years. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
goserelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07777263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07777263.